1 February 2024 - The February 2024 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The February issue of the Schedule includes a few major new/revised listings:

• Natalizumab (Tysabri) - new formulation
• Nivolumab with relatlimab (Opdualag) - new combination product
• Tebentafusp (Kimmtrak) - new medicine

Read Summary of PBS changes